Data Insights

Catequentinib hydrochloride by Advenchen Laboratories for Metastatic Pancreatic Cancer: Likelihood of Approval

Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Metastatic Pancreatic Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Metastatic Pancreatic Cancer

Data Insights

Catequentinib hydrochloride by Advenchen Laboratories for Oral Cancer: Likelihood of Approval

Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Oral Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Catequentinib Hydrochloride in Oral Cancer

Data Insights

Catequentinib hydrochloride by Advenchen Laboratories for Non-Small Cell Lung Cancer: Likelihood of Approval

Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Non-Small Cell Lung Cancer. According...

Data Insights

Catequentinib hydrochloride by Advenchen Laboratories for Solid Tumor: Likelihood of Approval

Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Solid Tumor. According to GlobalData,...

Data Insights

Catequentinib hydrochloride by Advenchen Laboratories for Small-Cell Lung Cancer: Likelihood of Approval

Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Small-Cell Lung Cancer. According to...

Data Insights

AL-8326 by Advenchen Laboratories for Head And Neck Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Head And Neck Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Head And Neck Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Non-Small Cell Lung Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Non-Small Cell Lung Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Solid Tumor: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Solid Tumor

Data Insights

AL-8326 by Advenchen Laboratories for Pancreatic Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Pancreatic Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Bladder Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Bladder Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Liver Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Liver Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Liver Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Small-Cell Lung Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Small-Cell Lung Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Cervical Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Cervical Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Prostate Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Prostate Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Ovarian Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Ovarian Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Breast Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Breast Cancer

Data Insights

AL-8326 by Advenchen Laboratories for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

AL-8326 by Advenchen Laboratories for Colon Cancer: Likelihood of Approval

AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Colon Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Colon Cancer